Results 31 to 40 of about 8,510 (199)

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs [PDF]

, 2021
Lorlatinib; Càncer de pulmó de cèl·lules no petites; ALK TKI de segona generacióLorlatinib; Cáncer de pulmón de células no pequeñas; ALK TKI de segunda generaciónLorlatinib; Non-small-cell lung cancer; Second-generation ALK TKIsBackground Lorlatinib, a ...
Bauman, J. R., Bearz, A., Camidge, D. R., Felip Font, Enriqueta, Shaw, A. T., Solomon, B. J.   +5 more
core   +1 more source

Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer [PDF]

, 2022
Tyrosine kinase inhibitors (TKIs) that target the ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene have shown dramatic therapeutic effects in patients with ROS1-rearranged non-small-cell lung cancer (NSCLC).
Ajimizu, Hitomi, Aoki, Wataru, Funazo, Tomoko, Hashimoto, Kentaro, Hirai, Toyohiro, Hosoya, Kazutaka, Itotani, Ryo, Kuninaga, Kiyomitsu, Ogimoto, Tatsuya, Ozasa, Hiroaki, Sakamori, Yuichi, Tsuji, Takahiro, Yamazoe, Masatoshi, Yoshida, Hironori, Yoshida, Hiroshi   +14 more
core   +1 more source

Population pharmacokinetic model with time‐varying clearance for lorlatinib using pooled data from patients with non‐small cell lung cancer and healthy participants

CPT: Pharmacometrics & Systems Pharmacology, 2021
Lorlatinib, a selective inhibitor of anaplastic lymphoma kinase (ALK) and c‐ROS oncogene 1 (ROS1) tyrosine kinase, is indicated for the treatment of ALK‐positive metastatic non‐small cell lung cancer (NSCLC) following progression on crizotinib and at ...
Joseph Chen, Brett Houk, Yazdi K. Pithavala, Ana Ruiz‐Garcia   +3 more
doaj   +1 more source

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN

JTO Clinical and Research Reports, 2023
Introduction: Lorlatinib, a third-generation ALK inhibitor, was found to have improved efficacy versus crizotinib in patients with previously untreated, advanced ALK-positive NSCLC in the ongoing, global, randomized, phase 3 CROWN study.
Hidetoshi Hayashi, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Toru Kumagai, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Satoshi Oizumi, MD, PhD, Masakazu Matsumura, MS, Masayuki Okura, PhD, Gerson Peltz, MD, MPH, Terufumi Kato, MD   +10 more
doaj   +1 more source

Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer [PDF]

, 2023
Lorlatinib; Non-small-cell lung cancerLorlatinib; Cáncer de pulmón de células no pequeñasLorlatinib; Càncer de pulmó de cèl·lules no petitesWhat is this summary about? This summary shows the updated results of an ongoing research study called CROWN that
Bauer, Todd, de Marinis, Filippo, FELIP, ENRIQUETA, Liu, Geoffrey, MAZIERES, JULIEN, Mok, Tony, Solomon, Benjamin   +6 more
core   +1 more source

Combination Therapies Targeting Alk-Aberrant Neuroblastoma in Preclinical Models. [PDF]

, 2023
BACKGROUND: ALK activating mutations are identified in approximately 10% of newly diagnosed neuroblastomas and ALK amplifications in a further 1-2% of cases.
Barker, K, Bellini, A, Bhalshankar, J, Calton, E, Carcaboso, AM, Che, H, Chen, L, Chesler, L, Decaudin, D, Del Nery, E, Delattre, O, Dhariwal, S, Gao, Q, Geoerger, B, George, SL, Gestraud, P, Goodman, A, Gorrini, C, Hutchinson, JC, Iddir, Y, Jamin, Y, Janoueix-Lerosey, I, Jiménez, I, Marques Da Costa, ME, Martins Da Costa, B, Némati, F, Pierre-Eugene, C, Poon, E, Saberi-Ansari, E, Saint-Charles, A, Schleiermacher, G, Shrestha, S, Surdez, D, Tucker, ER, Tweddle, DA   +34 more
core   +3 more sources

Inhibiting SCD expression by IGF1R during lorlatinib therapy sensitizes melanoma to ferroptosis

Redox Biology, 2023
Induction of ferroptosis is an emerging strategy to suppress melanoma progression. Strategies to enhance the sensitivity to ferroptosis induction would be a major advance in melanoma therapy.
Furong Zeng, Lin Ye, Qian Zhou, Yi He, Yilei Zhang, Guangtong Deng, Xiang Chen, Hong Liu   +7 more
doaj   +1 more source

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece [PDF]

Journal of Health Economics and Outcomes Research, 2022
**Background:** Non-small cell lung cancer (NSCLC), which accounts for about 80%-85% of lungcancer cases, is a leading cause of cancer-related death worldwide.
George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos, Georgia Kourlaba   +6 more
doaj   +2 more sources

The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain

Cancer Medicine, 2020
Objective To clarify the distribution of lorlatinib in the brain and elucidate the molecular mechanisms of lorlatinib penetration across the blood‐brain barrier (BBB).
Wei Chen, Dujia Jin, Yafei Shi, Yujun Zhang, Haiyan Zhou, Guohui Li   +5 more
doaj   +1 more source

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review

JTO Clinical and Research Reports, 2021
Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R.
Viola W. Zhu, MD, PhD, Misako Nagasaka, MD, Russell Madison, BA, Alexa B. Schrock, PhD, Jean Cui, PhD, Sai-Hong Ignatius Ou, MD, PhD   +5 more
doaj   +1 more source